Compare CRSP & FRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | FRO |
|---|---|---|
| Founded | 2013 | 1985 |
| Country | Switzerland | Cyprus |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.8B |
| IPO Year | 2016 | 1995 |
| Metric | CRSP | FRO |
|---|---|---|
| Price | $61.85 | $44.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 3 |
| Target Price | ★ $70.29 | $37.67 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-22-2026 |
| Dividend Yield | N/A | ★ 4.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | N/A |
| Revenue Next Year | $172.52 | N/A |
| P/E Ratio | ★ N/A | $34.05 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $19.87 |
| 52 Week High | $78.48 | $45.17 |
| Indicator | CRSP | FRO |
|---|---|---|
| Relative Strength Index (RSI) | 66.87 | 67.33 |
| Support Level | $50.17 | $33.79 |
| Resistance Level | $60.10 | N/A |
| Average True Range (ATR) | 2.13 | 1.27 |
| MACD | 0.89 | 0.49 |
| Stochastic Oscillator | 88.40 | 86.80 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.